Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
(WorldNews China)

PDF Version - QINLOCKTM Approved for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor and U.S. Commercial Launch Underway - - Reported QINLOCK Net Revenue of $4.8 Million in the First Partial Quarter of Launch - - Company Expects to Complete Enrollment in Phase 3 INTRIGUE Study in Fourth Quarter 2020 - - Second Quarter 2020 Ended with Cash, Cash Equivalents and Marketable Securities of $632 Million; Cash Runway Expected into the Second Half of 2022 - - Company to Host Conference Call Today at 4:30 PM ET - WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 4, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the second quarter ended June 30, 2020 and...